readthroughSign in
Nov 16, 2026People

Relmada names Jørn Skibsted Jakobsen chief development officer ahead of NDV-01 Phase 3

Relmada Therapeutics announced on November 16, 2026 that the former global clinical development leader of ADSTILADRIN will oversee the company's pipeline as it prepares a Phase 3 program for NDV-01 in bladder cancer.

Relmada Therapeutics, Inc. announced on November 16, 2026 the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen will lead clinical development across Relmada's pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.1

Jakobsen previously served as Head of Global Clinical Development for the pivotal program of Ferring Pharmaceuticals' ADSTILADRIN that culminated in approvals from the U.S. Food and Drug Administration, European Medicines Agency, Japan's Pharmaceuticals and Medical Devices Agency, and Health Canada for the treatment of non-muscle invasive bladder cancer.1 During a nine-year stint at Ferring, he oversaw global clinical development strategy, registrational studies, and regulatory interactions in that therapeutic area.1 He also directed the lifecycle expansion of ADSTILADRIN's clinical program into additional patient populations.1

Most recently he held the title of Vice President, Therapeutic Area Head, Urology & Uro-Oncology, at Ferring Pharmaceuticals1, where he also chaired the Scientific Advisory Committee of Ferring Ventures.1 Earlier in his career he was Chief Urologist at Herlev University Hospital in Denmark, treating patients with bladder and prostate cancer1, and before that a consultant urologist at Odense University Hospital.1

His academic credentials include an MD and PhD from the University of Southern Denmark and its Faculty of Health Sciences, along with a diploma in pharmaceutical medicine from the European Center of Pharmaceutical Medicine at the University of Basel, according to the release.

Relmada CEO Sergio Traversa said in the release that Jakobsen led the pivotal development program for ADSTILADRIN, described as the first intravesical gene therapy approved globally by the FDA, EMA, PMDA, and Health Canada for NMIBC, and that his regulatory experience would support preparations for the SPECTRUM Phase 3 program.1 Jakobsen said he was joining because he sees potential in NDV-01, citing Phase 2 results showing high, durable complete response rates alongside favorable safety and tolerability.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.